Abstract
mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 3419-3421 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 22 |
Issue number | 14 |
DOIs | |
State | Published - Jul 15 2016 |
ASJC Scopus subject areas
- Oncology
- Cancer Research